Alpha Tau Medical announced that Stephen Hahn, M.D., former commissioner of the U.S. Food and Drug Administration, FDA, has joined its Scientific Advisory Board. A distinguished expert in the field of radiation oncology and translational/clinical research, and a renowned physician, Dr. Hahn brings a wealth of regulatory and scientific experience to the Company as it advances its Alpha DaRT technology towards FDA clearance. Dr. Hahn is currently CEO-Partner of Flagship Pioneering and CEO of Harbinger Health, where he specializes in innovating in the field of preventive health care and global health strategy.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on DRTS:
- Alpha Tau Medical Ltd. Set for Major Advancements in Cancer Trials: A Comprehensive Overview of Ongoing Studies and Future Prospects
- Alpha Tau treats first patient with inoperable pancreatic cancer
- Alpha Tau Treats First Patient with Advanced Inoperable Pancreatic Cancer at Israel’s Hadassah Medical Center
- Alpha Tau files to sell 1.1M ordinary shares for holders
- Alpha Tau data adds to ‘robust list of evidence,’ says Cantor Fitzgerald
